Suppr超能文献

膀胱癌患者的生存率、治疗延迟评估、外科医生类型及治疗方式。

Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment.

作者信息

Gulliford M C, Petruckevitch A, Burney P G

机构信息

Department of Public Health Medicine, United Medical School, London.

出版信息

BMJ. 1991 Aug 24;303(6800):437-40. doi: 10.1136/bmj.303.6800.437.

Abstract

OBJECTIVE

To determine whether length of delay before treatment; specialty and grade of the surgeon; and use made of surgery, radiotherapy, and chemotherapy influenced the survival of patients with cancer of the bladder, after adjusting for case severity.

DESIGN

Retrospective cohort study.

SETTING

South East and South West Thames health regions.

PATIENTS

609 men aged under 75 resident in the South Thames regions who had been registered as new cases of bladder cancer in 1982, 35 of whom were excluded, leaving 574 eligible patients. Analysis was based on 75% retrieval rate for case notes.

MAIN OUTCOME MEASURES

Duration of survival from date of diagnosis of the bladder tumour.

RESULTS

10 prognostic variables were used to adjust for case severity. The median delay from referral to first treatment was 48 (interquartile range 27-84) days. Treatment after a short delay was associated with shorter survival because of the early treatment of more severe cases. Consultants treated 68% of patients, trainee surgeons treated less severe cases. Initial treatment was by a urologist in 67% of cases, but the specialty of the surgeon was not associated with prognosis. The associations of radiotherapy, cystectomy, and systemic chemotherapy with survival were interpreted in terms of selection bias as well as therapeutic effect.

CONCLUSION

Case severity was the most important influence on survival and influenced length of delay before treatment, grade and specialty of the surgeon, and main treatment allocation. After adjusting for case severity variations in these processes of care were not strongly associated with variations in survival.

摘要

目的

在对病例严重程度进行校正后,确定治疗前的延迟时间、外科医生的专业和级别以及手术、放疗和化疗的使用是否会影响膀胱癌患者的生存率。

设计

回顾性队列研究。

地点

泰晤士河南部和西南部健康区域。

患者

居住在泰晤士河南部地区的609名75岁以下男性,他们在1982年被登记为膀胱癌新病例,其中35人被排除,剩下574名符合条件的患者。分析基于病例记录75%的检索率。

主要观察指标

从膀胱肿瘤诊断日期起的生存时间。

结果

使用10个预后变量对病例严重程度进行校正。从转诊到首次治疗的中位延迟时间为48天(四分位间距27 - 84天)。延迟时间短的治疗与较短的生存期相关,因为更严重的病例得到了早期治疗。顾问医生治疗了68%的患者,实习外科医生治疗病情较轻的病例。67%的病例初始治疗由泌尿科医生进行,但外科医生的专业与预后无关。放疗、膀胱切除术和全身化疗与生存的关联在选择偏倚以及治疗效果方面得到了解释。

结论

病例严重程度是对生存的最重要影响因素,并且影响治疗前的延迟时间、外科医生的级别和专业以及主要治疗分配。在对病例严重程度进行校正后,这些医疗过程中的差异与生存差异没有强烈关联。

相似文献

3
Contributions of incidence and case fatality to mortality from bladder cancer in the south Thames Regions.
J Epidemiol Community Health. 1992 Aug;46(4):387-9. doi: 10.1136/jech.46.4.387.
4
Treatment delay and prognosis in invasive bladder cancer.
J Urol. 2005 Nov;174(5):1777-81; discussion 1781. doi: 10.1097/01.ju.0000177521.72678.61.
5
Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.
Eur Urol. 2014 Aug;66(2):361-70. doi: 10.1016/j.eururo.2013.09.050. Epub 2013 Oct 9.
6
Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network.
BJU Int. 2009 Mar;103(6):747-52. doi: 10.1111/j.1464-410X.2008.08241.x. Epub 2008 Dec 5.

引用本文的文献

3
Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer.
Gastric Cancer. 2019 Jul;22(4):864-872. doi: 10.1007/s10120-018-00910-y. Epub 2018 Dec 10.
4
Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.
Br J Cancer. 2015 Mar 31;112 Suppl 1(Suppl 1):S92-107. doi: 10.1038/bjc.2015.48.
5
Are alarm symptoms predictive of cancer survival?: population-based cohort study.
Br J Gen Pract. 2013 Dec;63(617):e807-12. doi: 10.3399/bjgp13X675197.
6
Survival analysis of patients with bladder cancer, life table approach.
J Midlife Health. 2012 Jul;3(2):88-92. doi: 10.4103/0976-7800.104468.
7
Management of concomitant cancer and abdominal aortic aneurysm.
Cardiol Res Pract. 2011 Apr 19;2011:516146. doi: 10.4061/2011/516146.
8
9
How will the two-weeks-wait rule affect delays in management of urological cancers?
J R Soc Med. 2003 Aug;96(8):398-9. doi: 10.1177/014107680309600809.
10
The reliability of cancer registry records.
Qual Health Care. 1996 Jun;5(2):120-1.

本文引用的文献

1
DELAY IN TREATING BLADDER TUMOURS.
Lancet. 1965 Aug 14;2(7407):332-4. doi: 10.1016/s0140-6736(65)90298-9.
2
Regional differences in survival from cancer.
Community Med. 1981 Nov;3(4):291-7.
3
Presenting symptoms, treatment delay and survival in bladder cancer.
Scand J Urol Nephrol. 1983;17(2):163-7. doi: 10.3109/00365598309180162.
4
T3 bladder cancer: salvage rather than elective cystectomy after radiotherapy.
Urology. 1984 Oct;24(4):315-20. doi: 10.1016/0090-4295(84)90199-7.
5
Geographical variation in mortality from conditions amenable to medical intervention in England and Wales.
Lancet. 1983 Mar 26;1(8326 Pt 1):691-6. doi: 10.1016/s0140-6736(83)91981-5.
6
Prognostic factors in superficial bladder cancer.
Prog Clin Biol Res. 1986;221:257-69.
7
Hospital inpatient mortality. Is it a predictor of quality?
N Engl J Med. 1987 Dec 24;317(26):1674-80. doi: 10.1056/NEJM198712243172626.
8
Adjusted hospital death rates: a potential screen for quality of medical care.
Am J Public Health. 1987 Sep;77(9):1162-6. doi: 10.2105/ajph.77.9.1162.
9
Selecting initial therapy for bladder cancer.
Cancer. 1987 Aug 1;60(3 Suppl):502-13. doi: 10.1002/1097-0142(19870801)60:3+<502::aid-cncr2820601512>3.0.co;2-w.
10
Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report.
Br J Urol. 1988 Dec;62(6):558-64. doi: 10.1111/j.1464-410x.1988.tb04426.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验